Vutrisiran (Amvuttra)

Key Messages

• Canada’s Drug Agency (CDA-AMC) recommends that Amvuttra be reimbursed by public drug plans for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adult patients if certain conditions are met.
• Amvuttra should only be covered for adults with confirmed diagnoses of ATTR-CM (wild-type or hereditary). Amvuttra should only be covered for patients who have mild to moderate heart failure symptoms (i.e., New York Heart Association [NYHA] classes I to III), and a history of heart failure that required treatment or hospitalization. Amvuttra should not be covered for patients who have had a heart or liver transplant, use a mechanical heart support device, or are already receiving other disease-modifying treatment for ATTR-CM (e.g., tafamidis).
• Amvuttra should only be reimbursed if it is prescribed by a specialist experienced in diagnosing and managing ATTR-CM and if the cost of Amvuttra does not exceed that of tafamidis. Amvuttra should be discontinued in patients whose disease progresses to NYHA class IV heart failure, who undergo a heart or liver transplant, or who receive an implanted cardiac mechanical assist device.
• Important budget impact considerations must be addressed for health systems to be able to adopt Amvuttra.